Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Acquisition of CyDex) (Details)

v2.4.0.8
Fair Value Measurements (Acquisition of CyDex) (Details) (Cydex Pharmaceuticals, Inc, USD $)
In Millions, unless otherwise specified
9 Months Ended 12 Months Ended
Sep. 30, 2014
Dec. 31, 2013
Credit Derivatives [Line Items]    
Amount Of Revenue For Contingent Consideration $ 15  
Contingent Consideration Classified as Equity
   
Credit Derivatives [Line Items]    
Revenue volatility 25.00% 25.00%
Average of probability of commercialization 83.80% 67.60%
Sales beta 0.60 0.60
Credit rating B BBB
Equity risk premium 6.00% 6.00%
Minimum | Contingent Consideration Classified as Equity
   
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing 17.9 [1] 4.2 [1]
Maximum | Contingent Consideration Classified as Equity
   
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing $ 20.5 [1] $ 19.8 [1]
[1] Revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement.